Back to results

Randomized AmnioFix Study During Radical Prostatectomy

Primary Purpose

Prostate Cancer

Status

Withdrawn

Phase

Phase 2

Locations

Study Type

Interventional

Intervention

Robotic Assisted Laparoscopic Radical Prostatectomy (RARP)

AmnioFix®

Questionnaire

About this trial

This is an interventional treatment trial for Prostate Cancer focused on measuring Prostate cancer, Dehydrated human amnion/chorion membrane, dHACM, Robotic assisted laparoscopic radical prostatectomy, RARP, AmnioFix®, Sexual function score, Neurovascular bundle inflammation, Questionnaire, Survey

Eligibility Criteria

35 Years - 75 Years (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

Male subjects between the ages 35-75
Primary diagnosis of prostate cancer selected for surgical intervention by one of the six protocol surgeons (Chapin, Davis, Matin, Pettaway, Pisters, Ward).
Have a willingness to comply with follow-up HRQOL (health related quality of life) surveys and PSA assessments.
Have ability to provide full written consent.
Primary diagnosis of untreated with clinically localized prostate cancer with Gleason score of 6, 7,8 or 9.
Planned elective radical prostatectomy with bilateral nerve sparing technique that can include high or low fascia.
Negative urinalysis within 30 days prior to date of surgery

Exclusion Criteria:

High-risk cancer planned for neoadjuvant therapy, full or partial excision of one or both neurovascular bundles.
Has any condition(s), which seriously compromises the subject's ability to participate in this study, sign consent, or has a known history of poor adherence with medical treatment.
Is unable to comply with learning and documenting penile rehabilitation, including oral 5-phosphodiesterase inhibitor use, vacuum pump therapy use, and/or injectable medications.
In the opinion of the PI, has a history of drug or alcohol abuse within last 12 months.
Is allergic to Aminoglycoside antibiotics (such as Gentamicin and/or Streptomycin).
Patients with a history of more than two weeks treatment with immuno-suppressants (including systemic corticosteroids), cytotoxic chemotherapy within one month prior to initial screening, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study.
Patients currently enrolled in another study. Concurrent enrollment in another study is prohibited expect for the control arm which can be used for other protocols with HRQOL endpoints with similar instruments.
Has had prior hormonal therapy such as Lupron or oral anti-androgens.
Unwilling to participate in follow-up clinical appointments at MDACC.

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Nerve Sparing RARP + AmnioFix®

Nerve Sparing RARP

Arm Description

Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP) plus placement of a 2x12 sheet of AmnioFix® to the neurovascular bundle.

Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP)

Outcomes

Primary Outcome Measures

Reducing Neurovascular Bundle Inflammation in Prostate Cancer Patients Undergoing Nerve Sparing Robotic Assisted Laparoscopic Radical Prostatectomy (RARP)

Outcome determined by a 10-point improvement in 3-month post-prostatectomy sexual function score using the Expanded Prostate Cancer Index Composite (EPIC) 26 in patients treated with the AmnioFix® graft compared to standard treatment.

Secondary Outcome Measures

Full Information

NCT ID

NCT02645591

First Posted

December 31, 2015

Last Updated

November 21, 2016

Sponsor

M.D. Anderson Cancer Center

Collaborators

MiMedx Group, Inc.

1. Study Identification

Unique Protocol Identification Number

NCT02645591

Brief Title

Randomized AmnioFix Study During Radical Prostatectomy

Official Title

Neurovascular Bundle Protection With an Amnion/Chorion Membrane Allograft to Improve Postoperative Functional Recovery: A Randomized Comparison to Standard Techniques

Study Type

Interventional

2. Study Status

Record Verification Date

November 2016

Overall Recruitment Status

Withdrawn

Study Start Date

November 2016 (undefined)

Primary Completion Date

November 2019 (Anticipated)

Study Completion Date

undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

M.D. Anderson Cancer Center

Collaborators

MiMedx Group, Inc.

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

The goal of this clinical research study is to learn about the safety and the effectiveness of using AmnioFix® (dehydrated human amnion/chorion membrane, also called dHACM) to help improve the return of erectile function and bladder control in patients after robotic assisted laparoscopic radical prostatectomy (RARP). dHACM is a section of tissue made from part of the placenta donated by a mother during a C-section. It looks like a small piece of tissue paper and is wrapped around the nerve bundles in the surgical area. The tissue may help the body's normal healing process.

Detailed Description

Study Groups: If participant is eligible and agrees to take part in the study, they will be randomly assigned (as in the flip of a coin) to 1 of 2 groups. Participant will have an equal chance of being in either group. This is done because no one knows if one study group is better, the same, or worse than the other group: If participant is in Group 1, they will have RARP with dHACM. If participant is in Group 2, they will have RARP alone. Participant will not be told which group they are assigned to until they reach the end of the study. Participant will sign a separate consent form for the surgery that explains the risks. During Surgery: If participant is in Group 1, the dHACM will be wrapped around the nerve bundles at the end of the surgery. For both groups, during the surgery, participant's surgeon may decide that RARP is not possible. In this case, participant will be taken off the study and dHACM will not be used. Information will also be collected during participant's surgery, such as details about their surgery, their hospital stay, and about any side effects that they may have. Study Visits: Participant will visit the study doctor for their standard follow-up visits after surgery at 6 weeks, 3 months, 6 months, and 12 months. At these visits, participant will complete the same questionnaire they completed at screening. At 24 months, participant's medical chart will be reviewed or they will be called on the phone to learn if the disease came back. If participant is called, the call should last about 5-10 minutes. Length of Study Participation: Patient's participation in the study will be over after the 24-month medical chart review or call. This is an investigational study. The dHACM is commercially available for use in various types of surgeries. Its use in prostate surgery to help improve the return of erectile function and bladder control in patients after RARP is investigational. Up to 100 participants will be enrolled in this study. All will take part at MD Anderson.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Prostate Cancer

Keywords

Prostate cancer, Dehydrated human amnion/chorion membrane, dHACM, Robotic assisted laparoscopic radical prostatectomy, RARP, AmnioFix®, Sexual function score, Neurovascular bundle inflammation, Questionnaire, Survey

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 2

Interventional Study Model

Parallel Assignment

Masking

Participant

Allocation

Randomized

Enrollment

0 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Nerve Sparing RARP + AmnioFix®

Arm Type

Experimental

Arm Description

Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP) plus placement of a 2x12 sheet of AmnioFix® to the neurovascular bundle.

Arm Title

Nerve Sparing RARP

Arm Type

Active Comparator

Arm Description

Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP)

Intervention Type

Procedure

Intervention Name(s)

Robotic Assisted Laparoscopic Radical Prostatectomy (RARP)

Other Intervention Name(s)

RALP

Intervention Description

Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP).

Intervention Type

Biological

Intervention Name(s)

AmnioFix®

Other Intervention Name(s)

Dehydrated Human Amnion/chorion Membrane, dHACM

Intervention Description

Dehydrated human amnion/chorion membrane (dHACM) wrapped around the nerve bundles at the end of Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP) surgery.

Intervention Type

Behavioral

Intervention Name(s)

Questionnaire

Other Intervention Name(s)

Survey

Intervention Description

Questionnaire completed about erectile function before surgery, and at 6 weeks, 3 months, 6 months, and 12 months after surgery.

Primary Outcome Measure Information:

Title

Reducing Neurovascular Bundle Inflammation in Prostate Cancer Patients Undergoing Nerve Sparing Robotic Assisted Laparoscopic Radical Prostatectomy (RARP)

Description

Time Frame

3 months

10. Eligibility

Sex

Male

Minimum Age & Unit of Time

35 Years

Maximum Age & Unit of Time

75 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Male subjects between the ages 35-75 Primary diagnosis of prostate cancer selected for surgical intervention by one of the six protocol surgeons (Chapin, Davis, Matin, Pettaway, Pisters, Ward). Have a willingness to comply with follow-up HRQOL (health related quality of life) surveys and PSA assessments. Have ability to provide full written consent. Primary diagnosis of untreated with clinically localized prostate cancer with Gleason score of 6, 7,8 or 9. Planned elective radical prostatectomy with bilateral nerve sparing technique that can include high or low fascia. Negative urinalysis within 30 days prior to date of surgery Exclusion Criteria: High-risk cancer planned for neoadjuvant therapy, full or partial excision of one or both neurovascular bundles. Has any condition(s), which seriously compromises the subject's ability to participate in this study, sign consent, or has a known history of poor adherence with medical treatment. Is unable to comply with learning and documenting penile rehabilitation, including oral 5-phosphodiesterase inhibitor use, vacuum pump therapy use, and/or injectable medications. In the opinion of the PI, has a history of drug or alcohol abuse within last 12 months. Is allergic to Aminoglycoside antibiotics (such as Gentamicin and/or Streptomycin). Patients with a history of more than two weeks treatment with immuno-suppressants (including systemic corticosteroids), cytotoxic chemotherapy within one month prior to initial screening, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study. Patients currently enrolled in another study. Concurrent enrollment in another study is prohibited expect for the control arm which can be used for other protocols with HRQOL endpoints with similar instruments. Has had prior hormonal therapy such as Lupron or oral anti-androgens. Unwilling to participate in follow-up clinical appointments at MDACC.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

John W. Davis, MD

Organizational Affiliation

M.D. Anderson Cancer Center

Official's Role

Principal Investigator

12. IPD Sharing Statement

Links:

URL

http://www.mdanderson.org

Description

University of Texas MD Anderson Cancer Center Website

Learn more about this trial

Randomized AmnioFix Study During Radical Prostatectomy

We'll reach out to this number within 24 hrs